The total return over the past 12 months is +116.12% vs. +16.94% for the S&P 500. So far it's up +61.01% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +116.12% | +105.36% | +50.88% | +20.54% | N/A | N/A |
| Total Return CAGR | +116.12% | +105.36% | +50.88% | +20.54% | N/A | N/A |
| Revenue CAGR | +34.81% | N/A | +59.63% | N/A | N/A | N/A |
| Net Income CAGR | +59.32% | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | +46.76% | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | +251.98% | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | +231.79% | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Protagonist Therapeutics, Inc. (PTGX)
| Year | Start price | End price | PTGX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $87.34 | $140.63 | +61.01% | +14.51% | +46.50% |
| 2025 | $38.60 | $87.34 | +126.27% | +17.72% | +108.55% |
| 2024 | $22.93 | $38.60 | +68.34% | +24.89% | +43.45% |
| 2023 | $10.91 | $22.93 | +110.17% | +26.19% | +83.98% |
| 2022 | $34.20 | $10.91 | (68.10%) | (18.17%) | (49.93%) |
| 2021 | $20.16 | $34.20 | +69.64% | +28.74% | +40.90% |
| 2020 | $7.05 | $20.16 | +185.96% | +18.37% | +167.59% |
| 2019 | $6.73 | $7.05 | +4.75% | +31.22% | (26.47%) |
| 2018 | $20.80 | $6.73 | (67.64%) | (4.56%) | (63.08%) |
| 2017 | $21.99 | $20.80 | (5.41%) | +21.70% | (27.11%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
